公开(公告)号：US20130225680A1

公开(公告)日：2013-08-29

申请号：US13858045

申请日：2013-04-06

申请人： Mahesh Kandula

发明人： Mahesh Kandula

IPC分类号： C07C327/30

CPC分类号： C07C321/10 ,  C07C321/20 ,  C07C323/41 ,  C07C327/22 ,  C07C327/30

摘要： The disclosure herein provides the compounds of Formulas 1 and its pharmaceutical acceptable salts, as well as polymorphs, solvates, and hydrates thereof. These salts may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for oral administration, transdermal administration, and/or injection. Such compositions may be used for the treatment of metabolic conditions, cystinosis, non-alcoholic Steatohepatitis, hypertriglyceridemia, and/or neurodegenerative disorders, and/or their associated complications.

摘要翻译： 本文的公开内容提供式1的化合物及其药学上可接受的盐，以及其多晶型物，溶剂合物和水合物。 这些盐可以配制成药物组合物。 药物组合物可以配制用于口服给药，透皮给药和/或注射。 这些组合物可用于治疗代谢病症，胱氨酸沉积症，非酒精性脂肪性肝炎，高甘油三酯血症和/或神经变性疾病和/或其相关并发症。

公开(公告)号：US20120172421A1

公开(公告)日：2012-07-05

申请号：US13418836

申请日：2012-03-13

申请人： Mahesh Kandula

发明人： Mahesh Kandula

IPC分类号： A61K31/385 ,  A61P9/00 ,  A61P19/00 ,  A61P27/02 ,  A61P13/12 ,  A61P17/00 ,  A61P25/00 ,  A61P35/04 ,  C07D339/02 ,  A61P29/00

CPC分类号： A61K31/385 ,  C07D339/04

摘要： The disclosure herein provides a compound of formula 1. The disclosure also provides a method of synthesizing the compound of formula 1. The compound of formula 1 or its pharmaceutical acceptable salts, as well as polymorphs, solvates, and hydrates thereof may be formulated as pharmaceutical composition. The pharmaceutical composition of compound of formula 1 or the final compound may be formulated for non-invasive peroral, topical (example transdermal), enteral, transmucosal, targeted delivery, sustained release delivery, delayed release, pulsed release and parenteral methods. Such compositions may be used to treat chronic pain manifested with chronic diseases or its associated complications. The compound may also be offered as a kit.

摘要翻译： 本文的公开内容提供式1的化合物。本公开还提供了合成式1化合物的方法。式1化合物或其药学上可接受的盐以及其多晶型物，溶剂化物和其水合物可以配制成药物 组成。 式1化合物或最终化合物的药物组合物可以配制用于非侵入性口服，局部（透皮），肠内，经粘膜，靶向递送，持续释放递送，延迟释放，脉冲释放和肠胃外方法。 这种组合物可用于治疗慢性疾病或其相关并发症所表现的慢性疼痛。 化合物也可以作为试剂盒提供。

公开(公告)号：US20110262976A1

公开(公告)日：2011-10-27

申请号：US12863349

申请日：2009-01-16

申请人： Mahesh Kandula ,  Mary E. Vaman Rao

发明人： Mahesh Kandula ,  Mary E. Vaman Rao

IPC分类号： C12P17/00 ,  C12N15/74 ,  C12N1/21

CPC分类号： C12P17/00 ,  C12N9/0008 ,  C12N9/1029 ,  C12N9/1085 ,  C12N9/13

摘要： This application provides systems and methods for the production of R-α-lipoic acid. Lipoic acid synthesis genes may be expressed in an acid-tolerant microorganism, such as Gluconobacter oxydans. The lipoic acid synthesis proteins may include LipA and SufE. The genetically engineered strain may be cultured under suitable culture conditions, such as in a mannitol medium with an acidic pH.

摘要翻译： 该应用提供用于生产R-α-硫辛酸的系统和方法。 硫辛酸合成基因可以在耐酸微生物如氧化葡糖杆菌中表达。 硫辛酸合成蛋白可以包括LipA和SufE。 遗传工程菌株可以在合适的培养条件下培养，例如在具有酸性pH的甘露醇培养基中。

公开(公告)号：US09725404B2

公开(公告)日：2017-08-08

申请号：US14591016

申请日：2015-01-07

申请人： Mahesh Kandula

发明人： Mahesh Kandula

IPC分类号： C07C69/608 ,  C07C211/10 ,  C07D295/027 ,  C07C57/03 ,  C07C69/587 ,  C07C69/60 ,  A61K47/48

CPC分类号： C07C211/10 ,  A61K47/541 ,  A61K47/542 ,  C07C57/03 ,  C07C69/587 ,  C07C69/60 ,  C07D295/02 ,  C07D295/027

摘要： The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of salts of formula I or formula II; and methods for treating or preventing multiple sclerosis may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of neurodegenerative diseases and psoriasis.

公开(公告)号：US09394288B2

公开(公告)日：2016-07-19

申请号：US14399170

申请日：2013-02-27

申请人： Mahesh Kandula

发明人： Mahesh Kandula

IPC分类号： C07D409/12 ,  A61K47/48 ,  A61K31/145 ,  A61K31/194 ,  A61K31/385 ,  A61K31/618 ,  A61K31/352 ,  A61K31/202 ,  A61K31/522 ,  A61K31/381 ,  C07D333/58

CPC分类号： C07D409/12 ,  A61K31/145 ,  A61K31/194 ,  A61K31/202 ,  A61K31/352 ,  A61K31/381 ,  A61K31/385 ,  A61K31/522 ,  A61K31/618 ,  A61K47/54 ,  A61K47/542 ,  A61K47/545 ,  C07D333/58 ,  A61K2300/00

摘要： The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of asthma and allergy may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of respiratory diseases, respiratory disorders, COPD, bronchitis, brain injury, inflammation, inflammatory skin diseases, asthma, allergic reactions, infections due to acute allergy, bronchospasm, respiratory distress, acute asthma, leukotrienes over activity, 5-LO enzyme activity and cancer.

摘要翻译： 本发明涉及式I化合物或其药学上可接受的盐，以及其多晶型物，溶剂合物，对映体，立体异构体和水合物。 包含有效量的式I化合物和用于治疗哮喘和过敏的药物组合物可以配制用于口服，口腔，直肠，局部，透皮，经粘膜，静脉内，肠胃外给药，糖浆或注射。 这些组合物可用于治疗呼吸系统疾病，呼吸系统疾病，COPD，支气管炎，脑损伤，炎症，炎性皮肤疾病，哮喘，过敏反应，急性过敏性感染，支气管痉挛，呼吸窘迫，急性哮喘，白细胞三烯超过活性， 5-LO酶活性和癌症。

公开(公告)号：US09339484B2

公开(公告)日：2016-05-17

申请号：US14399187

申请日：2013-02-16

申请人： Mahesh Kandula

发明人： Mahesh Kandula

IPC分类号： A61K31/222 ,  C07C235/40 ,  C07C235/60 ,  C07D339/04 ,  A61K31/135 ,  A61K31/197 ,  A61K31/202 ,  A61K31/232 ,  A61K31/24 ,  A61K31/385 ,  A61K31/44 ,  A61K31/616 ,  A61K31/618 ,  A61K45/06

CPC分类号： A61K31/222 ,  A61K31/135 ,  A61K31/197 ,  A61K31/202 ,  A61K31/232 ,  A61K31/24 ,  A61K31/385 ,  A61K31/44 ,  A61K31/616 ,  A61K31/618 ,  A61K45/06 ,  C07C235/60 ,  C07C2601/14 ,  C07D339/04 ,  A61K2300/00

摘要： The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of fibromyalgia, restless leg syndrome may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of motor neurone disease, diabetic neuropathy, postherpetic neuralgia, acute opioid withdrawal management, obsessive-compulsive disorder, premature ejaculation, PTSD, injury, post-operative pain, osteoarthritis, rheumatoid arthritis, multiple sclerosis, spinal cord injury, migraine, HIV related neuropathic pain, bipolar depression, depression, stress, cancer pain and lower back pain.

摘要翻译： 本发明涉及式I化合物或其药学上可接受的盐，以及其多晶型物，溶剂合物，对映体，立体异构体和水合物。 包含有效量的式I化合物的药物组合物，以及用于治疗纤维肌痛，不宁腿综合征的方法可以配制用于口服，口腔，直肠，局部，透皮，经粘膜，静脉内，肠胃外给药，糖浆或注射。 此类组合物可用于治疗运动神经元疾病，糖尿病性神经病，带状疱疹后神经痛，急性阿片类药物戒断管理，强迫症，早泄，PTSD，损伤，手术后疼痛，骨关节炎，类风湿性关节炎，多发性硬化，脊髓 损伤，偏头痛，艾滋病相关神经性疼痛，双相抑郁，抑郁，压力，癌症疼痛和腰痛。

公开(公告)号：US20160122313A1

公开(公告)日：2016-05-05

申请号：US14533128

申请日：2014-11-05

申请人： Mahesh Kandula

发明人： Mahesh Kandula

IPC分类号： C07D339/04 ,  C07C323/57 ,  C07C233/63

CPC分类号： C07D339/04 ,  C07B2200/09 ,  C07C233/63 ,  C07C2601/04

摘要： The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for treating or preventing diabetes may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of metabolic syndrome, insulin resistance, glucose intolerance, hyperinsulinemia, diabetes mellitus, diabetes insipidus, hyperglycemia and diabetic complications.

摘要翻译： 本发明涉及式I化合物或其药学上可接受的盐，以及其多晶型物，溶剂合物，对映体，立体异构体和水合物。 包含有效量的式I化合物的药物组合物，以及用于治疗或预防糖尿病的方法可以配制用于口服，口腔，直肠，局部，透皮，经粘膜，静脉内，肠胃外给药，糖浆或注射。 此类组合物可用于治疗代谢综合征，胰岛素抵抗，葡萄糖耐受不良，高胰岛素血症，糖尿病，尿崩症，高血糖症和糖尿病并发症。

公开(公告)号：US20160122291A1

公开(公告)日：2016-05-05

申请号：US14533116

申请日：2014-11-05

申请人： Mahesh Kandula

发明人： Mahesh Kandula

IPC分类号： C07C271/22

CPC分类号： C07C271/22 ,  C07C271/00 ,  C07C271/16 ,  C07D339/04

摘要： The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I or formula II; and methods for treating or preventing multiple sclerosis may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of neurodegenerative diseases and other neuro-inflammatory diseases.

摘要翻译： 本发明涉及式I和式II化合物或其药学上可接受的盐，以及多晶型物，溶剂合物，对映体，立体异构体和水合物。 药物组合物包含有效量的式I或式II化合物; 并且可以配制用于治疗或预防多发性硬化的方法用于口服，口腔，直肠，局部，透皮，经粘膜，静脉内，肠胃外给药，糖浆或注射。 这样的组合物可用于治疗神经变性疾病和其它神经炎症性疾病。

公开(公告)号：US20160120838A1

公开(公告)日：2016-05-05

申请号：US14533111

申请日：2014-11-05

申请人： Mahesh Kandula

发明人： Mahesh Kandula

IPC分类号： A61K31/235 ,  A61K45/06 ,  C07C233/55 ,  C07C233/54 ,  C07C251/72

CPC分类号： A61K31/245 ,  A61K31/202 ,  A61K31/235 ,  A61K31/606 ,  A61K31/655 ,  A61K45/06 ,  C07C233/54 ,  C07C233/55 ,  C07C235/74 ,  C07C243/22 ,  C07C251/86 ,  C07C2601/16 ,  A61K2300/00

摘要： The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I or formula II; and methods for treating or preventing inflammatory bowel disease may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of gastrointestinal diseases and inflammation such as inflammatory bowel disease, ulcerative colitis, mild-to-moderate Crohn's disease, rheumatoid arthritis, inflammatory arthritis, psoriatic arthritis, liver cirrhosis and idiopathic urticaria.

公开(公告)号：US20160115115A1

公开(公告)日：2016-04-28

申请号：US14591016

申请日：2015-01-07

申请人： Mahesh Kandula

发明人： Mahesh Kandula

IPC分类号： C07C69/604 ,  C07C57/03 ,  C07C211/10 ,  C07D295/027

CPC分类号： C07C211/10 ,  A61K47/541 ,  A61K47/542 ,  C07C57/03 ,  C07C69/587 ,  C07C69/60 ,  C07D295/02 ,  C07D295/027

摘要： The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of salts of formula I or formula II; and methods for treating or preventing multiple sclerosis may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of neurodegenerative diseases and psoriasis.

摘要翻译： 本发明涉及式I和式II化合物或其药学上可接受的多晶型物，溶剂合物，对映体，立体异构体和水合物。 包含有效量的式I或式II的盐的药物组合物; 并且可以配制用于治疗或预防多发性硬化的方法用于口服，口腔，直肠，局部，透皮，经粘膜，静脉内，肠胃外给药，糖浆或注射。 这样的组合物可用于治疗神经变性疾病和牛皮癣。